KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)
- Citation:
- Clin Cancer Res vol 20 (11) 3033-3043
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 984
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- CA33601, K05CA-142885, U10 CA031946, U10 CA033601, U10 CA037404, U10 CA180821, U24 CA114740, CA-114740, CA-25224, U10 CA180790, P30 CA015083, P30 CA016058, K05 CA142885, U10 CA025224, CA31946, CA37404
- Corr. Author:
- Authors:
- Harry H. Yoon David Tougeron Qian Shi Steven R. Alberts Michelle R. Mahoney Garth D. Nelson Suresh G. Nair Stephen N. Thibodeau Richard M. Goldberg Daniel J. Sargent Frank A. Sinicrope
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- KRAS, colon cancer, prognosis, BRAF, survival